MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

50.05 +0.54 (+1.09%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 114,790
Open 49.70
Bid (Size) 49.98 (100)
Ask (Size) 50.10 (600)
Prev. Close 49.51
Today's Range 49.50 - 50.20
52wk Range 30.04 - 78.48
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗
The gene-editing stock has been in a tailspin of late. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
Via Finterra
Topics Intellectual Property

Performance

YTD
-6.9%
-6.9%
1 Month
-11.4%
-11.4%
3 Month
-9.2%
-9.2%
6 Month
-28.7%
-28.7%
1 Year
+54.6%
+54.6%

More News

Read More
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
Via The Motley Fool
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗
Via The Motley Fool
News headline image
Why Is CRSP Stock Falling Pre-Market Today? ↗
Via Stocktwits
News headline image
RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗
Via Stocktwits
Topics Electric Vehicles
News headline image
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
Via The Motley Fool
News headline image
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Via The Motley Fool
Topics ETFs
News headline image
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗
Via The Motley Fool
News headline image
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
Via The Motley Fool
Topics ETFs
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
Via MarketBeat
News headline image
Should You Buy Shares of CRISPR Therapeutics in February? ↗
Via The Motley Fool
News headline image
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗
Via Benzinga
News headline image
2 Biotech Stocks That Could Soar This Year ↗
Via The Motley Fool
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗
Via The Motley Fool
News headline image
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
Via PredictStreet
Topics Economy

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 50.05
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 04/06/26 10:03 AM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 3.95B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story